Latest news

Filters (16)
June 16, 2021

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

Read more
June 14, 2021

Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies

Read more
March 1, 2021

Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant

Read more
February 25, 2021

Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients

Read more
September 17, 2020

Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress

Read more
August 26, 2020

Debiopharm’s New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer

Read more
June 10, 2020

Debiopharm’s novel microbiome remodeling program licensed to Takeda for the treatment of gastrointestinal disorders

Read more
March 25, 2020

Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy

Read more
March 5, 2020

Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor

Read more